Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News Analysis
Nature Reviews Drug Discovery 7, 378–379 (1 May 2008) | doi:10.1038/nrd2585
News in Brief
Abstract
Cancer vaccines make progress US- or EU-approved therapeutic cancer vaccines could be available in 2009. The lowdown: Dendreon received positive news in March 2008 when the FDA agreed to a protocol amendment that would speed up the delivery of the final results of the Phase III trial — IMPACT, Immunotherapy for Prostate AdenoCarcinoma Treatment — of Provenge (sipuleucel-T).
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
